Literature DB >> 8439321

Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors.

H Gitay-Goren1, R Halaban, G Neufeld.   

Abstract

Vascular endothelial growth factor (VEGF) is a specific mitogen for endothelial cells in vitro and an angiogenic factor in vivo. Its role in other cell types is not yet clear. To explore its possible involvement in malignant transformation, we studied the expression of its receptors in normal and malignant melanocytes. Binding and cross-linking experiments showed that human melanoma cells but not normal melanocytes express VEGF receptors. Separation of reaction products by SDS-PAGE demonstrated the presence of 125I-VEGF/receptor complexes of 180 and 165 kDa in the melanoma cells. A diffuse complex with a mass of approximately 235 kDa was also detected in some experiments. Heparin enhanced the binding of the radioactive ligand to the receptors of the WW94 and SW1614 melanoma cell lines. This binding was completely abolished by heparinase digestion and was restored by the addition of exogenous heparin, indicating that heparin-like molecules are necessary for ligand/receptor interaction. This study suggests that the aberrant expression of VEGF receptors is one of the phenotypic changes occurring in melanoma cells during malignant transformation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8439321     DOI: 10.1006/bbrc.1993.1106

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  34 in total

Review 1.  Angiogenesis and melanoma.

Authors:  J P Dutcher
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

2.  Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas.

Authors:  O Straume; L A Akslen
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

3.  Angiogenesis and melanoma - from basic science to clinical trials.

Authors:  Maxine Sylvia Emmett; Daemon Dewing; Rowan Oliver Pritchard-Jones
Journal:  Am J Cancer Res       Date:  2011-08-08       Impact factor: 6.166

4.  Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor.

Authors:  Marcella Marcellini; Naomi De Luca; Teresa Riccioni; Alessandro Ciucci; Angela Orecchia; Pedro Miguel Lacal; Federica Ruffini; Maurizio Pesce; Francesca Cianfarani; Giovanna Zambruno; Augusto Orlandi; Cristina Maria Failla
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

5.  What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis?

Authors:  R F Nicosia
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

6.  Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays.

Authors:  Janice M Mehnert; Mary M McCarthy; Lucia Jilaveanu; Keith T Flaherty; Saadia Aziz; Robert L Camp; David L Rimm; Harriet M Kluger
Journal:  Hum Pathol       Date:  2009-12-11       Impact factor: 3.466

7.  Phase II trial of vorinostat in advanced melanoma.

Authors:  N B Haas; I Quirt; S Hotte; E McWhirter; R Polintan; S Litwin; P D Adams; T McBryan; L Wang; L P Martin; M vonMehren; R K Alpaugh; J Zweibel; A Oza
Journal:  Invest New Drugs       Date:  2014-01-25       Impact factor: 3.850

8.  The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.

Authors:  Una Adamcic; Karolina Skowronski; Craig Peters; Jodi Morrison; Brenda L Coomber
Journal:  Neoplasia       Date:  2012-07       Impact factor: 5.715

9.  Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.

Authors:  Lucia Jilaveanu; Christopher Zito; Sandra J Lee; Katherine L Nathanson; Robert L Camp; David L Rimm; Keith T Flaherty; Harriet M Kluger
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

Review 10.  Perlecan and tumor angiogenesis.

Authors:  Xinnong Jiang; John R Couchman
Journal:  J Histochem Cytochem       Date:  2003-11       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.